Brookstone Capital Management Purchases New Stake in Elanco Animal Health Incorporated $ELAN

Brookstone Capital Management acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,373 shares of the company’s stock, valued at approximately $665,000.

A number of other large investors have also recently made changes to their positions in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Elanco Animal Health during the first quarter valued at about $2,065,000. Goldman Sachs Group Inc. raised its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after acquiring an additional 76,408 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Elanco Animal Health by 59.9% in the 2nd quarter. American Century Companies Inc. now owns 203,567 shares of the company’s stock valued at $2,907,000 after acquiring an additional 76,230 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Up 0.1%

Shares of NYSE:ELAN opened at $23.11 on Monday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $27.72. The company has a market capitalization of $11.49 billion, a PE ratio of -48.14, a price-to-earnings-growth ratio of 2.94 and a beta of 1.88. The business has a fifty day moving average price of $24.56 and a two-hundred day moving average price of $22.85. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ELAN. KeyCorp boosted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Barclays began coverage on Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Leerink Partners upped their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. increased their price target on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.